Research / MHLA / Fundamental state Inspectable configuration
State dimensions Filing 0001412100-23-000056 Insurance
Cash RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.cash
$24.2M · CORE · NOT_ENOUGH_HISTORY
Debt RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.gross_debt
$254.6M · OPTIONAL · NOT_ENOUGH_HISTORY
Premium growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.insurance.premiums
702.32% · CORE · NOT_ENOUGH_HISTORY
Revenue growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.fundamentals.revenue
93.98% · CORE · NOT_ENOUGH_HISTORY
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 12 states History building
Jun 30, 2022 0/5 normalized Level 3 Sep 30, 2022 0/5 normalized Level 3 Dec 31, 2022 0/6 normalized Level 3 Mar 31, 2023 0/4 normalized Level 3 Jun 30, 2023 2/6 normalized Level 3 Sep 30, 2023 2/5 normalized Level 3 Dec 31, 2023 2/5 normalized Level 3 Mar 31, 2024 2/5 normalized Level 3 Jun 30, 2024 4/5 normalized Level 3 Sep 30, 2024 4/5 normalized Level 3 Dec 31, 2024 5/5 normalized Level 3 Mar 31, 2025 5/6 normalized Level 3 Period transition
What moved in the state? Cash Decreased
Previous $31.0M
Current $24.2M
Delta -$6.8M Debt Decreased
Previous $255.6M
Current $254.6M
Delta -$953,000 Premium Growth Increased
Previous -28.80%
Current 702.32%
Delta 731.12% Revenue Growth Increased
Previous -41.11%
Current 93.98%
Delta 135.09% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.